Background: Local ablative treatment to limited metastatic or oligometastatic patients can result in long term disease-free survival in colorectal and sarcoma patients. The importance of consolidating all macroscopic tumor deposits in prostate cancer in the modern era is an unanswered question. Stereotactic ablative radiation (SABR) is highly focused, high-dose radiation that is ideally suited for treatment of oligometastatic patients. Here we report on the safety and preliminary clinical outcomes of a modern cohort of oligometastatic prostate cancer (OPC) patients treated with consolidative SABR at a single institution.
